Compare · BIIB vs VCEL
BIIB vs VCEL
Side-by-side comparison of Biogen Inc. (BIIB) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.52B, about 12.6x VCEL ($2.34B).
- Over the past year, BIIB is up 62.9% and VCEL is up 29.4% - BIIB leads by 33.5 points.
- BIIB has been more active in the news (14 items in the past 4 weeks vs 5 for VCEL).
- BIIB has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- Biogen Inc.
- Vericel Corporation
- Price
- $199.87-2.99%
- $45.85-1.69%
- Market cap
- $29.52B
- $2.34B
- 1M return
- +0.66%
- +16.99%
- 1Y return
- +62.90%
- +29.37%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 14
- 5
- Recent ratings
- 25
- 11
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Latest VCEL
- Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
- Principal Accounting Officer Siegal Jonathan exercised 2,500 shares at a strike of $29.82 and sold $122,667 worth of shares (2,732 units at $44.90) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 886 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $223,750 worth of shares (5,000 units at $44.75) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 16,009 units (SEC Form 4)
- Chief Medical Officer Hopper Jonathan Mark sold $450,000 worth of shares (10,000 units at $45.00) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $29.82 (SEC Form 4)
- Chief Legal Officer Flynn Sean C. exercised 15,000 shares at a strike of $16.25 and sold $684,600 worth of shares (15,000 units at $45.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Halpin Michael exercised 10,000 shares at a strike of $16.66 and sold $402,400 worth of shares (10,000 units at $40.24) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Flynn Sean C. exercised 15,000 shares at a strike of $16.25 and sold $603,150 worth of shares (15,000 units at $40.21) as part of a pre-agreed trading plan (SEC Form 4)
- The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
- Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
- Chief Medical Officer Hopper Jonathan Mark exercised 4,375 shares at a strike of $16.66 and sold $153,125 worth of shares (4,375 units at $35.00) as part of a pre-agreed trading plan (SEC Form 4)